Earnings Call Summary | Addex Therapeutics(ADXN.US) Q4 2023 Earnings Conference
Earnings Call Summary | Addex Therapeutics(ADXN.US) Q4 2023 Earnings Conference
The following is a summary of the Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript:
以下是Addex Therapeutics Ltd（ADXN）2023年第四季度業績電話會議記錄的摘要：
Financial Performance:
財務業績：
Addex secured CHF5 million by spinning out its unpartnered preclinical portfolio into a new private company, Neurosterix.
R&D expenses reduced from CHF14.7 million in 2022 to CHF7 million in 2023 due to termination of Dipraglurant development for Parkinson's disease.
G&A expenses reduced from CHF7.3 million in 2022 to CHF5 million in 2023 due to decreased D&O insurance costs.
Addex將其未合作的臨床前投資組合分拆給一家新的私營公司Neurosterix，從而獲得了500萬瑞士法郎的融資。
由於帕金森氏病的Dipraglurant開發終止，研發費用從2022年的1470萬瑞士法郎減少到2023年的700萬瑞士法郎。
由於 D&O 保險成本降低，G&A 費用從 2022 年的 730 萬瑞士法郎減少到 2023 年的 500 萬瑞士法郎。
Business Progress:
業務進展：
Addex is awaiting data from the Phase 2 epilepsy clinical study conducted by partner, Janssen.
Addex identified post-stroke recovery as a potential area for future development of Dipraglurant and is currently profiling it in preclinical models.
Extension of the GABAB PAM Indivior collaboration funded Addex with additional CHF2.7 million for research.
Addex plans to advance multiple drug candidates into IND enabling studies in H2 2024.
With the launch of Neurosterix with a $63 million Series A financing round, Addex plans to progress its preclinical portfolio without diluting its clinical-stage asset and partner program.
Addex Therapeutics is in talks with potential partners for Dipraglurant in PD-LID and post-stroke recovery. It also plans to move M4 PAM program through Phase 1 development.
Addex正在等待合作伙伴詹森進行的2期癲癇臨床研究的數據。
Addex將中風後康復確定爲Dipraglurant未來開發的潛在領域，目前正在臨床前模型中對其進行分析。
GABAB PAM Indivior合作的延期爲Addex提供了額外的270萬瑞士法郎用於研究。
Addex計劃在2024年下半年將多種候選藥物推進到支持IND的研究。
隨着Neurosterix的推出，提供6,300萬美元的A輪融資，Addex計劃在不稀釋其臨床階段資產和合作夥伴計劃的情況下推進其臨床前投資組合。
Addex Therapeutics正在與潛在合作伙伴就Dipraglurant在PD-LID和中風後康復方面的潛在合作伙伴進行談判。它還計劃將M4 PAM計劃推向第一階段的開發。
More details: Addex Therapeutics IR
更多詳情： Addex 治療公司 IR
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由 AI 生成。無法完全保證內容的準確性。欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。